144 related articles for article (PubMed ID: 31361813)
1. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
4. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients.
Gates RS; Lollar DI; Collier BR; Smith J; Faulks ER; Gillen JR
J Trauma Acute Care Surg; 2022 Jan; 92(1):93-97. PubMed ID: 34561398
[TBL] [Abstract][Full Text] [Related]
6. Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
May CC; Cua S; Smetana KS; Powers CJ
World Neurosurg; 2022 Jan; 157():e357-e363. PubMed ID: 34655821
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
[TBL] [Abstract][Full Text] [Related]
8. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children.
Greene LA; Law C; Jung M; Walton S; Ignjatovic V; Monagle P; Raffini LJ
J Thromb Haemost; 2014 Sep; 12(9):1554-7. PubMed ID: 24943261
[TBL] [Abstract][Full Text] [Related]
9. Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa.
Mazhar F; Ahmed Y
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):169-170. PubMed ID: 27936527
[No Abstract] [Full Text] [Related]
10. Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
Andrade-Campos MM; Montes-Limón AE; Fernandez-Mosteirin N; Salvador-Osuna C; Torres M; Lucia-Cuesta JF; Rubio-Felix D
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):194-8. PubMed ID: 23358201
[TBL] [Abstract][Full Text] [Related]
11. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
12. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
Israel EN; Thomas CA; Mastropietro CW
Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
Stephenson ML; Serra AE; Neeper JM; Caballero DC; McNulty J
J Perinatol; 2016 Feb; 36(2):95-9. PubMed ID: 26658126
[TBL] [Abstract][Full Text] [Related]
14. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
15. IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
Diab YA; Ramakrishnan K; Ferrell B; Chounoune R; Alfares FA; Endicott KM; Rooney S; Corcoran J; Zurakowski D; Berger JT; Shankar V; Nath DS
Pediatr Crit Care Med; 2017 May; 18(5):e207-e214. PubMed ID: 28296662
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.
van Oosterom N; Winckel K; Barras M
J Thromb Thrombolysis; 2019 Oct; 48(3):387-393. PubMed ID: 30945098
[TBL] [Abstract][Full Text] [Related]
17. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
[TBL] [Abstract][Full Text] [Related]
19. Residual Enoxaparin Activity, Anti-Xa Levels, and Concerns About the American Society of Regional Anesthesia and Pain Medicine Anticoagulation Guidelines.
Henshaw DS; Turner JD; Forest DJ; Thompson GR; Weller RS
Reg Anesth Pain Med; 2017; 42(4):432-436. PubMed ID: 28492441
[TBL] [Abstract][Full Text] [Related]
20. Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient.
Rahawi KW; Higgins KL; Noda C; Stultz JS
Pharmacotherapy; 2017 Apr; 37(4):e16-e20. PubMed ID: 28152224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
